

# Amplification of *SOX4* promotes PI3K/Akt signaling in human breast cancer

Gaurav A. Mehta<sup>1,2,3</sup> · Joel S. Parker<sup>4</sup> · Grace O. Silva<sup>4</sup> · Katherine A. Hoadley<sup>4</sup> · Charles M. Perou<sup>4</sup> · Michael L. Gatza<sup>1,2,3</sup>

Received: 16 November 2016 / Accepted: 2 February 2017  
© Springer Science+Business Media New York 2017

## Abstract

**Purpose** The PI3K/Akt signaling axis contributes to the dysregulation of many dominant features in breast cancer including cell proliferation, survival, metabolism, motility, and genomic instability. While multiple studies have demonstrated that basal-like or triple-negative breast tumors have uniformly high PI3K/Akt activity, genomic alterations that mediate dysregulation of this pathway in this subset of highly aggressive breast tumors remain to be determined.

**Methods** In this study, we present an integrated genomic analysis based on the use of a PI3K gene expression signature as a framework to analyze orthogonal genomic data from human breast tumors, including RNA expression, DNA copy number alterations, and protein expression. In combination with data from a genome-wide RNA-mediated interference screen in human breast cancer cell lines, we identified essential genetic drivers of PI3K/Akt signaling.

**Results** Our in silico analyses identified *SOX4* amplification as a novel modulator of PI3K/Akt signaling in breast cancers and in vitro studies confirmed its role in regulating Akt phosphorylation.

**Conclusions** Taken together, these data establish a role for *SOX4*-mediated PI3K/Akt signaling in breast cancer and suggest that *SOX4* may represent a novel therapeutic target and/or biomarker for current PI3K family therapies.

**Keywords** Breast cancer · Genomics · *SOX4* · PI3 kinase · Akt

## Introduction

Breast cancer heterogeneity can be observed clinically by widely varying therapeutic responses and at a molecular level by the myriad of genetic alterations driving tumorigenesis [1–6]. Clinically, triple-negative breast cancer (TNBC), which is largely synonymous with the basal-like molecular subtype of breast cancer, accounts for 15–20% of breast tumors representing ~20,000 new cases and ~10,000 deaths each year in the United States [3, 7]. Given the lack of drug-able targets expressed by TNBC tumors, including the lack of estrogen receptor (ER) and the HER2 oncogene, few therapeutic options exist beyond currently utilized cytotoxic therapies, and the overall prognosis for these patients remains poor.

Many previous studies, including The Cancer Genome Atlas (TCGA) project, have reported increased phosphatidylinositol-3-OH kinase (PI3K) signaling in basal-like tumors. This pathway mediates, among other processes, cell cycle progression and survival, [3, 8–10] and is highly activated in this subset of tumors despite a low incidence (~7%) of *PIK3CA* activation mutations. While studies

---

**Electronic supplementary material** The online version of this article (doi:10.1007/s10549-017-4139-2) contains supplementary material, which is available to authorized users.

---

✉ Michael L. Gatza  
michael.gatza@cinj.rutgers.edu

- <sup>1</sup> Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, CINJ 4558, New Brunswick, NJ 08903, USA
- <sup>2</sup> Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
- <sup>3</sup> Rutgers, The State University of New Jersey, New Brunswick, NJ, USA
- <sup>4</sup> Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

from the TCGA and others have noted copy number alterations or mutations in *PTEN* (35%), *INPP4B* (30%) and activation of multiple receptor tyrosine kinases, including *EGFR* (7%), *ERBB2* (4%), and *IGF1R* (2%), in addition to other mutations that may affect aberrant PI3K signaling in basal-like tumors, it remains to be determined whether additional mechanisms may contribute to pathway activity and/or the observed lack of response to PI3K family inhibitors [3, 8, 11–14].

To identify genomic alterations mediating PI3K/Akt signaling, specifically those that may represent novel therapeutic targets and/or biomarkers to current therapies, we utilized an integrative genomic strategy based on experimentally derived gene expression signatures [6]. By analyzing orthogonal proteomic and genomic data from the TCGA in conjunction with data from a genome-wide RNAi proliferation screen in breast cancer cell lines, we identified *SOX4* as a putative novel regulator of PI3K/Akt signaling and in vitro studies confirmed the role of this gene in mediating Akt phosphorylation.

## Materials and methods

### Gene expression data

RNA sequencing data ( $n = 1031$ ) from human tumors (Supplemental Table 1) were acquired from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>) and processed as previously described [15]. PAM50 classification as well as calculation of the PI3K [6, 16], PIK3CA [17], PTEN Deleted, and PTEN Wildtype [18] signatures was performed as previously described [1, 6, 19]. Illumina HT-29 v3 expression data for the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) project ( $n = 1992$ ) was acquired from the European Genome-phenome Archive at the European Bioinformatics Institute (<https://www.ebi.ac.uk/ega/>), and data were median centered [4]. Expression data for a panel of 51 breast cancer cell lines was acquired from GEO (GSE12777) [20]. Affymetrix U133+2 data were MAS5.0 normalized using Affymetrix Expression Console (ver1.2.1.20), and  $\log_2$  transformed. Expression probes were collapsed using the median gene value with the GenePattern [21] module CollapseProbes.

### Reverse Phase Protein Array (RPPA) data

RPPA data were acquired (October 24, 2013) from The Cancer Proteome Atlas data portal ([http://app1.bioinformatics.mdanderson.org/tcpa/\\_design/basic/index.html](http://app1.bioinformatics.mdanderson.org/tcpa/_design/basic/index.html)). Replication-based normalized RPPA data ( $n = 733$ ) containing expression levels for 187 proteins and phosphorylated proteins

(Supplementary Table 1) were used to identify differentially expressed proteins. Samples were separated into high (top quartile) and low (all other) subgroups based on pathway score and a  $t$  test used to assess differences in expression for each protein. Additionally, a Spearman's rank correlation was used to compare the overall correlation between pathway activity and protein expression.

### Affymetrix SNP 6.0 copy number data

Affymetrix SNP 6.0-derived copy number data (Firehose run April 16, 2014) were acquired from the Firehose data portal (<http://gdac.broadinstitute.org/>) for the 1031 samples (Supplementary Table 1) for which both CN and gene expression data were available. Pathway-specific CN alterations were identified as previously described [6]. Briefly, a Spearman's rank correlation (both positive and negative) was used to compare gene-level segment scores with pathway activity score. Second, the frequency of copy number gains (including high-level amplification and gains) or losses (loss of heterozygosity or deletion), as determined by GISTIC 2.0 [22], in samples with high (top quartile) and low (all others) pathway activity was calculated by a Fisher's exact test. To identify genes that were significant across both methods, a threshold of  $q < 0.05$  was set for validation and  $q < 0.01$  for discovery.

### Genome-wide RNAi proliferation data

To identify genes required for cell viability in a pathway-dependent manner, data from a genome-wide RNAi screen in a panel of breast cancer cell lines were analyzed [6, 23]. The Gene Activity Ranking Profile (GARP) normalized data were obtained from the DPSC (Donnelly-Princess Margaret Screening Centre) data portal (<http://dpsc.ccb.utoronto.ca/cancer/index.html>) and filtered to include those 27 cell lines for which gene expression data (GSE12777) were also available (acquired February 2013). A negative Spearman correlation was used to compare pathway score and GARP score for each sample to identify genes essential for pathway-dependent cell proliferation. A threshold of  $p < 0.05$  was considered significant.

### Cell culture and siRNA knockdown

HCC38, HCC1143, and MDAMB468 cells were purchased from the American Tissue Culture Collection (Manassas, VA, USA). Cells were cultured in either RPMI-1640 medium with 10% fetal bovine serum and 1% penicillin/streptomycin (HCC38 and HCC1143) or DMEM/F12 medium with 10% fetal bovine serum and 1% penicillin/streptomycin (MDAMB468). Cells were sub-cultured at 60–70% confluence for siRNA transfections. Lipofectamine RNAiMAX

(ThermoFisher) was used to transfect cells with 40 nm of SMART pool siRNA targeting *SOX4* (M011779010005) or scrambled control (D0012061305) according to manufacturer's instructions (Dharmacon) for 48 h prior to RNA or protein isolation.

### Western blot

Cells were harvested using Triton lysis buffer containing 25 mM HEPES, 100 mM NaCl, 1 mM EDTA, 10% glycerol, and 1% Triton X-100 with 1× protease and phosphatase inhibitor added fresh prior to use. 50 µg of protein was loaded on 4–20% Mini-protean TGX gradient gel (BioRad) at 100 V for 2 h at room temperature and transferred onto nitrocellulose membrane at 100 V for 1 h at 4°C. The membranes were blocked using 5% milk solution, incubated with primary antibody against pAkt, total Akt, and beta-actin (Cell Signaling Technology) overnight at 4°C followed by incubation with HRP-conjugated secondary antibodies (Cell Signaling Technology) for 1 h at room temperature. The signal was developed using SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific), digitally imaged using the ChemiDoc Touch Imaging System (BioRad) and signaling intensity quantified by ImageJ software (<https://imagej.nih.gov/ij/>).

### Immunofluorescence

Cells were grown on coverslips, fixed with 4% paraformaldehyde in PBS, and permeabilized with 0.25% Triton X-100 in PBS for 8 min at room temperature. Cells were blocked in 1% BSA in PBS with 0.05% Tween 20 for 45 min at room temperature, incubated with anti-SOX4 (Santa Cruz, sc-17326) and anti-pAKT (Cell Signaling, 9271S) antibodies (1 h, room temperature), and then incubated with fluorochrome-labeled secondary antibodies for 1 h (room temperature). The coverslips were counterstained with DAPI and imaged with a Nikon Eclipse TE-2000U fluorescent microscope.

### Quantitative real-time PCR


Total RNA was isolated using RNeasy plus Mini Kit (Qiagen) and cDNA was synthesized using the QuantiTect Reverse Transcription kit (Qiagen). Quantitative PCR (qPCR) was performed and analyzed using Applied Biosystems 7500 real-time thermal cycler system. Human *SOX4* primer sequences are as follows: Forward: 5'-CTCTCCAGCCTGGGAATAA-3', Reverse: 5'-CGGAGGTGGGTAAGAGAGAA-3' and human *GAPDH* are Forward: 5'-TCTGACTTCAACAGCGA-CAC-3', Reverse: 5'-CCAGCCACATACCAGGAAAT-3'.

## Results

### PI3K gene expression signature corresponds with PI3K/Akt signaling in vivo

We used four previously published PI3K gene expression signatures, PI3K [6, 16], PIK3CA [17], PTEN wild-type (PTEN<sup>WT</sup>), and PTEN Deleted (PTEN<sup>DEL</sup>) [18], to calculate PI3K pathway activity in 1031 human breast tumor samples (Supplementary Table 1) from the TCGA project for which the PAM50 intrinsic subtypes [19, 24] were determined (Fig. 1a). Although each signature was independently developed [6, 17, 18], consistent patterns of pathway activity were observed across molecular subtypes with basal-like tumors being characterized by uniformly high levels of PI3K activity; increased signaling was also observed in HER2-Enriched (HER2E) and Luminal B (LumB) tumors, and significant differences were noted between each subtype (Supplementary Fig. 1). Despite the fact that each signature was developed using different strategies, identifying differentially expressed genes when comparing either GFP expressing cell lines to mutant [17] or wild-type [6, 16] *PIK3CA* expressing cells or by comparing *PTEN* wild-type and deleted tumors [18], signature scores were moderately concordant ( $r = 0.4–0.67$ ) across the data (Fig. 1b; Supplementary Fig. 2).

Focusing on the PI3K signature [6, 16], we confirmed the ability of the mRNA signature to accurately assess functional activation of the pathway by examining relationships between the gene expression signature score and proteins and phosphoprotein expression. Analysis of Reverse Phase Protein Array (RPPA) data from breast tumors ( $n = 733$ ), using both a Spearman correlation (comparing pathway score to protein expression level) and  $t$  test (top quartile against all other samples), confirmed that tumors with a high PI3K score have significantly lower levels of PTEN and INPP4B protein expression, consistent with role of these proteins as negative regulators of PI3K/Akt signaling. Despite lower levels of total Akt and no differences in the expression of the p110-alpha or p85 kinase subunits, tumors with high pathway score expressed significantly higher levels of phosphorylated (p) Akt at S473 and T308 (Fig. 1c; Supplementary Table 2). In addition, a number of known drivers of PI3K activity, including EGFR (pY1068 and pY1173), FOXM1, NOTCH1, cKIT, SYK, SRC (pY416), and c-MET (pY1235), had significantly higher levels of protein expression in tumors with a high PI3K score. Importantly, we also observed increased levels ( $p < 0.05$ ) of activated Akt substrates including PRAS40 (pT246), p27 (pT198), and YB1 (pS102) as well as further down-stream targets S6 (pS235-S236 and pS240-S244) and 4EBP1 (pT70) (Fig. 1c; Supplementary Table 2) [8, 10].




**Fig. 1** PI3K gene expression signature correlates with protein expression of PI3K/Akt pathway and is up-regulated in basal-like and HER2E tumors. **a** Patterns of PI3K signaling in breast cancer ( $n = 1031$ ) correspond with molecular subtype with basal-like (red) and HER2E (pink) having the highest levels, Luminal B (light blue) and Normal-like (NL, green) having intermediate levels, and LumA (dark blue) having the lowest levels. Tumors show consistent patterns of pathway activity across independent gene expression signatures.

**b** PI3K pathway gene expression signatures are strongly correlated as calculated by a Pearson correlation. **c** PI3K signature ( $n = 733$ ) corresponds with protein and phosphorylated protein expression of PI3K/Akt signaling pathway components. A *t* test (double dagger) was used to assess protein expression levels between the top quartile and all other samples, and a Spearman's rank correlation (single dagger) was used to assess the overall relationship between pathway score and RPPA expression level

## Identification of copy number alterations associated with PI3K signaling

We next sought to identify PI3K-specific copy number (CN) alterations (CNA), including known and potential novel drivers of pathway activity (Fig. 2a). Using our previously published strategy [6], breast tumor samples ( $n = 1031$ ) from the TCGA project were dichotomized into those with high (top quartile) or low (all others) pathway score, and the frequency of copy number gains (including high-level amplification and gains) or losses (including homozygous deletion and loss of heterozygosity) was calculated for each group (Fig. 2b) using a Fisher's exact test (Fig. 2c). Second, a Spearman Rank

Correlation was used to assess the overall relationship between PI3K pathway score and gene-level segment value (Fig. 2c). To reduce potential false positives associated with either strategy alone, we focused on those alterations that were significant ( $q < 0.05$ ), in both analyses; genes with an increased incidence of CN gains in samples with high PI3K pathway activity (top quartile) and a positive correlation with pathway activity were considered putative drivers of PI3K signaling, whereas those genes with an increased frequency of CN losses in tumors with a high PI3K score and a negative correlation were considered potential repressors of PI3K activity. These analyses allow for the identification of chromosomal alterations that are uniquely evident in the context of PI3K



**Fig. 2** PI3K score identifies PI3K/Akt specific copy number changes. **a** Overview of method for identifying PI3K-specific CNA. **b** The frequency of copy number gains (including amplification and gains) and losses (both deletion and LOH) were calculated for each gene in the top quartile (black line) and all other samples (gray line); frequencies are plotted according to chromosomal position. **c** A

Fisher's exact test was used to assess differences in the frequency of copy number gains (black line) or losses (dark blue line) between the top quartile and all other samples. A positive (red line) or negative (light blue line) Spearman's rank correlation was used to assess the overall relationship between pathway score and gene-level copy number expression

signaling while eliminating those regions that, while potentially altered at a high frequency, are not associated with altered signaling. For instance, 50.4% of patients with high PI3K activity but only 25.0% of tumors with low pathway activity have an amplification of chromosome 3q26, which contains *PIK3CA* ( $q_{\text{Fisher}} = 1.5 \times 10^{-12}$ ;  $q_{\text{Spearman}} = 4.0 \times 10^{-10}$ ). Beyond *PIK3CA* amplification, we also identified CNA ( $q < 0.05$ ) of known drivers of PI3K signaling including amplification of *KRAS*, *PTK2*, and *FOXM1* as well as losses of pathway inhibitors *PTEN*, *INPP4B*, and *PIK3R1* (Fig. 2b, Supplementary Table 3). Collectively, these data suggest that this strategy is able to identify CNA of known PI3K signaling components and may identify CNA of novel regulators of this pathway.

### Identification of potential essential, novel regulators of PI3K pathway activity

Our previous results identified DNA copy number aberrations that correlate with PI3K activity (Fig. 2). By analyzing functional data from a genome-wide RNA-mediated interference (RNAi) screen, we are able to identify specific genes within each amplicon that are essential for cell viability in a pathway-dependent manner. For these analyses, we employed data from a genome-wide RNAi proliferation screen (~16 k genes) performed in a panel of 27 breast cancer cell lines [23] for which matching mRNA expression data (GSE12777) was available (Fig. 2). For each cell line, the PI3K pathway score was calculated, and a negative Spearman's rank correlation was used to identify those genes required for cell proliferation in a PI3K-dependent manner. Our analyses identified known PI3K/Akt signaling components including *PYK2* (Fig. 3a,  $p = 0.003$ ) [25] as well as both *EIF4E* (Fig. 3b,  $p = 0.004$ ) and *RPS6* (Fig. 3c,  $p = 0.05$ ), which are prominent down-stream targets of Akt activity thereby validating this strategy.


Next, we used these functional data to prioritize candidate genes within each amplicon associated with PI3K activity. To do so, we compared the subset of genes that were amplified in a greater percentage ( $q < 0.01$ ) of samples with high PI3K pathway activity, had a positive correlation between PI3K signature score and CN segment score ( $q < 0.01$ ), and were required for cell viability ( $p < 0.05$ ) in a PI3K-dependent manner (Fig. 3d). This subset of genes was further restricted to those that also showed a positive correlation between DNA CN status and mRNA expression (Fig. 3e) based on the reasoning that a potential regulator of pathway activity must not only be amplified but also have increased mRNA expression (Supplementary Table 4). Of the identified candidate genes, several, including *NEDD9*, which has

been reported [26] to serve as a scaffolding protein for Akt and required for breast cancer genesis, have been reported to play a role in PI3K/Akt signaling. These data provide evidence that this strategy has the potential to identify both known and potentially novel mediators of PI3K/Akt signaling.

### *SOX4* is a putative driver of PI3K/AKT signaling

Among the candidate, genes identified on chromosome 6p22 was *SOX4* (sex-determining region Y-related high-mobility-group box transcription factor 4), which is a previously described oncogenic transcription factor that has been reported to correlate with a poor clinical outcome in human breast cancer and other cancers [27, 28]. We determined that *SOX4* CN positively correlated with PI3K score (Fig. 4a) and mRNA expression (Fig. 4b). In total, 41.5% of tumors with high pathway activity (top quartile) were characterized by *SOX4* CN gain compared to 22.6% of all other samples ( $q = 2.5 \times 10^{-08}$ ) (Fig. 4c). This appears to be largely a subtype-specific event as 68.1% of tumors with high PI3K activity and amplified *SOX4* were basal-like (Fig. 4d); in total, 57.2% of all basal-like tumors were characterized by *SOX4* amplification (Supplementary Fig. 3). Furthermore, *SOX4* amplified tumors had the highest levels of *SOX4* mRNA (Fig. 4e,  $p = 4.0 \times 10^{-23}$ , ANOVA;  $p < 0.0001$ ) and highest levels of PI3K activity (Supplementary Fig. 4,  $p = 3.7 \times 10^{-08}$ , ANOVA;  $p < 0.0001$ ). Analyses of the METABRIC [4] dataset ( $n = 1992$ ) demonstrated a comparable significant correlation between PI3K pathway score and *SOX4* expression ( $r = 0.42$ ,  $p = 2.6 \times 10^{-87}$ ), and *SOX4* CN status ( $r = 0.23$ ,  $p = 1.1 \times 10^{-24}$ ), respectively, as well as between *SOX4* expression and CN ( $r = 0.27$ ,  $p = 1.5 \times 10^{-34}$ ), thereby validating our findings in an independent cohort (Supplementary Fig. 5). Importantly, our analyses of data from a genome-wide RNAi screen demonstrated that breast cancer cell lines with high PI3K activity have a greater dependency ( $p = 0.048$ ) on *SOX4* than cell lines with low PI3K activity (Fig. 4f).

Finally, examining the coincidence of *SOX4* amplification with copy number alterations of known drivers of PI3K signaling demonstrated that the frequency of *SOX4* amplification in tumors with high (or low) PI3K activity was comparable ( $q < 0.05$ ) to that of *PIK3CA* (50.4 vs. 25.0%), *PTEN* (46.9 vs. 25.5%), or *INPP4B* (37.6 vs. 24.8%) CNA (Fig. 4a). These alterations, however, were neither mutually inclusive nor mutually exclusive as *SOX4* was solely altered (19.1%) at a comparable frequency to *PTEN* (23.6%) or *INPP4B* (18.7%) loss, or *PIK3CA* gain (21.7%) alone (Supplementary Fig. 6).



**Fig. 3** Identification of amplified and essential genes associated with PI3K signature. Identification of genes essential for cell viability in RNAi screen of breast cancer cell lines ( $n = 27$ ) in the context of PI3K signature as calculated by negative Spearman correlation ( $p < 0.05$ ) including **a** *PKY2* ( $p = 0.003$ ), **b** *EIF4E* ( $p = 0.004$ ), and **c** *RPS6* ( $p = 0.05$ ). The height of each bar indicates shRNA abundance (and cell viability) for each cell line grown in the presence

of gene-specific shRNA relative to control shRNA. **d** Schematic outlining the strategy used to identify amplified, essential pathway-specific genes. **e** Venn diagram identifying subset of amplified ( $q < 0.01$ ,  $n = 5350$ ) and essential ( $n = 590$ ) candidate genes that have a positive ( $p < 0.05$ ) correlation between mRNA expression and copy number level ( $n = 100$ )

### Increased PI3K/AKT signaling in breast tumor samples with amplified *SOX4*


We next determine whether patients with amplified *SOX4* are characterized by increased expression of Akt substrate proteins relative to those tumors that have a normal copy number. Analysis of RPPA-based protein expression in breast tumors with amplified ( $n = 198$ ) and normal ( $n = 431$ ) *SOX4* (Fig. 5a) demonstrated up-regulation of pAkt substrates in *SOX4*-amplified tumors including pPRAS40 pT246 ( $p = 0.01$ ); p27 pT157 ( $p = 0.004$ ) and pT198 ( $p = 1.8 \times 10^{-05}$ ); and ARAF pS299 ( $p = 0.02$ ). Furthermore, we determined that down-stream targets p4EBP1 [both pS65 ( $p = 0.001$ ) and pT37 ( $p = 4.8 \times 10^{-05}$ )] and pS6 at pS235-pS236 ( $p = 0.001$ ) and pS240-S244 ( $p = 0.0007$ ) were also up-regulated in

*SOX4*-amplified tumors. Consistent with these findings, we determined that tumors characterized by loss of *PTEN* ( $n = 227$ ), relative to samples with normal *PTEN* ( $n = 436$ ), showed consistent up-regulation of this subset of Akt substrates and down-stream target proteins (Fig. 5b). As such, these data support the association of *SOX4* with altered PI3K/Akt signaling.

### *SOX4* mediates PI3K/Akt signaling in basal-like breast cancer

In order to confirm that *SOX4* contributes to altered PI3K signaling, we utilized gene expression data from a panel of 51 breast cancer cell lines (GSE12777) to identify those with the highest PI3K score (Supplementary Fig. 7). Of these, basal-like cell lines, HCC38 and HCC1143 both

**Fig. 4** Identification of *SOX4* amplification as a putative driver of PI3K/Akt signaling. **a** Copy number alterations of modulators of PI3K/Akt signaling *PIK3CA*, *PTEN*, *INPP4B* as well as *SOX4* copy number status correlates ( $q < 0.01$ ) with PI3K score (hash). **b** *SOX4* mRNA expression correlates with PI3K score and *SOX4* gene-level copy number segment score (asterisks). **c** *SOX4* is amplified at a significantly greater frequency of samples with high (top quartile) PI3K pathway activity (41.5%) compared to all other samples (22.6%) ( $q = 2.5 \times 10^{-08}$ ). **d** Samples with an amplification of *SOX4* are predominantly (68.1%) basal-like tumors. **e** *SOX4* mRNA expression correlates with *SOX4* copy number status ( $p = 3.4 \times 10^{-23}$ ). (F) *SOX4* is essential for cell viability in breast cancer cell lines with high PI3K pathway activity. Higher expression of the PI3K Score is associated with lower *SOX4* shRNA abundance (Spearman correlation,  $p = 0.048$ )




have high PI3K signature score and high *SOX4* expression, whereas MDAMB468 cells have high PI3K activity but low (below the dataset median) *SOX4* expression. In addition to high PI3K activity, each of these cell lines are characterized by either loss of *PTEN* (HCC38) or *EGFR* activation (HCC1143) or both *PTEN* loss and *EGFR* activation (MDAMB468).

Using these cell lines, we examined the effects of siRNA-mediated silencing of *SOX4* on Akt phosphorylation. Quantitative Real-time PCR (qRT-PCR) confirmed that cells transfected with pooled siRNA comprised a panel of four individual siRNA targeting *SOX4* resulted in a significant decrease in *SOX4* expression in HCC38 (90%,  $p = 0.002$ , paired  $t$  test), HCC1143 (79%,  $p = 0.003$ , paired  $t$  test), and MDAMB468 (70%,  $p = 0.0001$ , paired  $t$  test) cells, respectively, relative to scrambled control (siC)-transfected cells (Fig. 6a). Loss of *SOX4* resulted in a

significant reduction in Akt phosphorylation in both HCC38 and HCC1143, while no change in pAkt levels were observed in MDAMB468 cells; total Akt or  $\beta$ -actin levels were unaffected (Fig. 6b). Quantitative analyses of pAkt levels relative to total Akt (Fig. 6c) demonstrated that loss of *SOX4* resulted in a 54–56% reduction in pAkt levels, relative to siC-treated cells, in HCC38 ( $p = 0.0008$ ) and HCC1143 ( $p = 0.005$ ), respectively, while no quantifiable change was observed in MDAMB468 cells ( $p = 0.53$ ).

Analysis of siC and siSOX4-treated cells by immunofluorescent microscopy (IF) further demonstrates that *SOX4* is largely undetectable in siSOX4-treated HCC38 cells, and this loss of *SOX4* protein expression corresponds with nearly an equal reduction in the levels of pAkt (Fig. 6d). Interestingly, the subset of siSOX4-treated HCC38 cells which retain detectable levels of *SOX4* also express pAkt suggesting that

**Fig. 5** *SOX4*-amplified tumors are characterized by increased PI3K/Akt protein and phosphoprotein expression. **a** Breast cancer samples with a *SOX4* copy number gain ( $n = 198$ ) had increased levels of expression of active or phosphorylated Akt substrates (both direct and down-stream targets) compared to samples with normal levels of *SOX4* ( $n = 431$ ). **b** Comparable patterns (as determined by unpaired *t* test) were observed in samples with a loss of *PTEN* ( $n = 227$ ) compared to tumors with normal *PTEN* copy number status ( $n = 436$ )



our western blot analyses may underestimate the total effect of *SOX4* on pAkt levels and when compared on a cell to cell basis, *SOX4* has a more dramatic effect on the phosphorylation of Akt. As shown in Supplementary Fig. 8, similar effects on pAkt levels were observed after *SOX4* silencing in HCC1143 cells.


## Discussion

PI3K/Akt/mTOR signaling regulates many predominant features of cancer including cellular proliferation, survival, metabolism, motility, and genomic instability [8, 9]. This pathway not only contributes to tumor development, but also plays an essential role in regulating therapeutic resistance in breast cancer [29–31]. Not surprisingly, there has been a significant effort to elucidate mechanisms regulating PI3K signaling in order to identify potential therapeutic targets and/or biomarkers to current therapies.

Improper activation of this pathway occurs through various molecular mechanisms including, among others, *PIK3CA* activating mutations; *PTEN* silencing mutations; and/or copy number changes in *PIK3CA*, *PTEN*, *INPP4B*, or *AKT2*, depending on the type and/or subtype of cancer [8–10]. In breast cancer, approximately 45% of patients are characterized by *PIK3CA*-activating mutations [1, 3];

however, these alterations are largely limited to LumA tumors and the link between these mutations and pathway activation is unclear as there is no correlation with known markers of pathway activity including pAkt, pS6, or p4EBP1 [3, 32–34]. In contrast, basal-like or TNBC tumors are characterized by increased PI3K activity and have increased expression of these markers despite the fact that these tumors rarely have *PIK3CA* activating mutations [3, 12]. While clinical studies have demonstrated that the combination of everolimus plus exemestane resulted in an improved prognosis for patients with advanced stage, ER+ luminal breast cancer [35–37], similar success has not been achieved in TNBC.

In the current study, we sought to identify genomic alterations that contribute to PI3K/Akt signaling and which may represent putative therapeutic opportunities. To address this challenge, we analyzed genomic data from more than 1000 breast tumor samples from the TCGA [1, 3] within the framework of an experimentally derived PI3K gene expression signature [6]. These in silico analyses identified *SOX4* as putative novel regulator of PI3K signaling, and this association was validated in an independent cohort of nearly 2000 breast tumor samples [4]. Since altered expression of this gene predominantly occurs in basal-like tumors, these data, consistent with previous studies demonstrating increased *SOX4* expression in



**Fig. 6** Sox4 mediates pAkt expression in vitro. **a** *SOX4* mRNA levels were determined by quantitative RT-PCR in HCC38 ( $p = 0.002$ ), HCC1143 ( $p = 0.0158$ ), and MDA-MB-468 ( $p = 0.0041$ ) cells transfected with either 40 nm of control siRNA (siC) or with siRNA against *SOX4* (siSOX4) for 48 h. Fold changes are relative to those of cells transfected with control siRNA, and significance was calculated using paired  $t$  test. **b** Immunoblot analyses of pAkt (S473), total Akt, and  $\beta$ -actin expression in cell lines with high (HCC38, HCC1143) and low (MDA-MB-468) *SOX4* expression following transfection with

either siC or siSOX4. Intensity of the signal was measured for each protein by ImageJ, and pAkt (S473) expression was analyzed relative to Total AKT (**c**) for HCC38 ( $p = 0.002$ ), HCC1143 ( $p = 0.005$ ), and MDA-MB-468 ( $p = 0.5310$ ) cell lines. **d** Immunofluorescence microscopy was used to analyze the effects of siC or siSOX4 in HCC38 cells on *SOX4* (Cy3) or pAkt (Cy5) protein expression, and cell nuclei were visualized by DAPI; scale bar 100  $\mu$ m. Images are shown at  $\times 20$  magnification (*left*) and digitally enlarged to show detail (*right*)

TNBC, suggest that this may be a subtype-specific event [38].

*SOX4* is a member of the group C family of SOX transcription factors which play an essential role in development but are reported to be over-expressed in many human cancers, including breast cancer where expression

correlates with tumor grade, stage, and prognosis [27, 28, 39]. Previous studies have reported that *SOX4* contributes to tumor development and progression through a number of mechanisms. *SOX4* has been shown to be essential in maintenance of stemness in cancer initiating cells, in driving cell proliferation, by promoting cell

migration and metastasis and, more recently, through induction of epithelial-to-mesenchymal transition (EMT) in breast cancer [38, 40–43]. While these previous studies have demonstrated a significant role for *SOX4* in tumor development, the current study is first to identify *SOX4* as a mediator of PI3K/Akt signaling in breast cancer. These results are consistent with recent work that demonstrates a role for *SOX4* in regulating PI3K activity in Ph+ ALL (Acute Lymphoblastic Leukemia) [44].

Experimental studies demonstrate that *SOX4* regulates pAkt expression in breast cancer cell lines with high *SOX4* expression irrespective of whether these cells are characterized by loss of *PTEN* or activation of *EGFR*. While the exact mechanism by which *SOX4* modulates PI3K/Akt signaling remains to be determined, a number of recent studies offer insight into several potential mechanisms. The role of *SOX4* as a transcription factor suggests that its effect on the PI3K pathway is mediated through regulation at the transcript level. However, given that our data demonstrate a clear loss of phosphorylated Akt in the absence of *SOX4* expression, but no discernible difference in total Akt, the effect of *SOX4* on signaling appears to be up-stream of Akt. It was recently reported that *SOX4* cooperates with *PTEN* loss to mediate prostate cancer tumorigenesis [45]; however, given that we see a comparable effect on *SOX4*-mediated Akt phosphorylation in both *PTEN* normal and *PTEN* deleted cells, it is unclear whether this is also true in breast cancer. The potential does exist that *SOX4* could mediate *PTEN* activity. In fact, studies in hepatocellular carcinoma recently reported that *SOX4* can modulate *HUNK* kinase (Hormonally up-regulated Neu-associated kinase) expression, which itself, has been shown to regulate Akt signaling in breast cancer by repressing *PTEN* activity [46, 47]. Unfortunately, we see no difference in *HUNK* mRNA expression in *SOX4* amplified and normal breast tumors.

Alternatively, a number of studies have suggested that *SOX4* can mediate activation of potential up-stream drivers of PI3K signaling including transcriptional activation of *EGFR* [48]. Despite these findings in prostate cancer, we see a *SOX4*-mediated effect on pAkt levels in both *EGFR*-activated and normal breast cancer cell lines. Moreover, we do not see a difference in pEGFR protein expression in *SOX4*-amplified or normal breast tumors. Although these data do not eliminate the possibility that *SOX4* mediates its effect on pAkt through *EGFR*, or another receptor tyrosine kinase, it suggests that alternative breast cancer-specific mechanisms may exist. Perhaps not surprising, recent analyses have also shown little concordance between genes regulated by *SOX4* across tissues type including prostate, lung, hepatocellular carcinoma, and adenoid cystic carcinoma [27, 28]. Thus, these results suggest the effects of *SOX4* on PI3K signaling may be affected by tissue specific

features. As such, additional studies must be undertaken to delineate these breast cancer-specific mechanisms.

Collectively, our cross-platform analyses of orthogonal genomic and proteomic data, along with in vitro studies, have identified and validated *SOX4* amplification as a mediator of PI3K/Akt signaling in breast cancer. While the precise mechanisms by which *SOX4* modulates PI3K activity in breast cancer remain unknown, our data, in combination with previous studies, suggest not only that an emphasis should be placed on elucidating these mechanisms but also that *SOX4*, or its down-stream targets, may be a putative therapeutic target and/or biomarker in breast cancer patients whose tumors are characterized by high PI3K activity.

**Acknowledgements** We thank members of our laboratory for helpful discussion and suggestions. Research reported in this publication was supported by the National Cancer Institute of the US National Institutes of Health (R00-CA166228), V Foundation for Cancer Research (V2016-013), and from the New Jersey Health Foundation (PC-52-16) to M.L.G. Additional funding for research reported in this study was provided by the National Cancer Institute of the US National Institutes of Health Breast SPORE program grant P50-CA58223-09A1 and R01-CA148761-04, as well as grants from the Susan G. Komen for the Cure and the Breast Cancer Research Foundation to C.M.P.

**Author contribution** G.A.M., J.S.P., C.M.P., and M.L.G. conceived and designed the study. G.A.M., G.O.S., K.A.H., and M.L.G. performed analyses and experiments. G.A.M., C.M.P., and M.L.G. wrote the manuscript. All authors have reviewed and approved the final manuscript.

#### Compliance with ethical standards

**Conflicts of interest** C.M.P. is an equity stock holder and board of director member of BioClassifier LLC and GeneCentric Diagnostics. C.M.P. is also listed as an inventor on a patent application for the PAM50 molecular assay. J.S.P. is also listed as an inventor on a patent application for the PAM50 molecular assay. All other authors declare no conflicts of interest.

## References

1. Ciriello G et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. *Cell* 163(2):506–519
2. Perou CM et al (2000) Molecular portraits of human breast tumors. *Nature* 406:747–752
3. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. *Nature* 490(7418):61–70
4. Curtis C et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. *Nature* 486(7403):346–352
5. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 98(19):10869–10874
6. Gatz ML et al (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat Genet* 46(10):1051–1059

7. DeSantis CE et al (2014) Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin* 64(4):252–271
8. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Discov* 13(2):140–156
9. Rodon J et al (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. *Nat Rev Clin Oncol* 10(3):143–153
10. Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. *Curr Opin Genet Dev* 20(1):87–90
11. Mertins P et al (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. *Nature* 534(7605):55–62
12. Weigman VJ et al (2012) Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. *Breast Cancer Res Treat* 133(3):865–880
13. Lopez-Knowles E et al (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. *Int J Cancer* 126(5):1121–1131
14. Marty B et al (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. *Breast Cancer Res* 10(6):R101
15. Hoadley KA et al (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell* 158(4):929–944
16. Gatz ML et al (2010) A pathway-based classification of human breast cancer. *Proc Natl Acad Sci* 107:6994–6999
17. Huttunen JE et al (2012) Oncogenic PI3K mutations lead to NF- $\kappa$ B-dependent cytokine expression following growth factor deprivation. *Cancer Res* 72(13):3260–3269
18. Saal LH et al (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. *Proc Natl Acad Sci USA* 104(18):7564–7569
19. Parker JS et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol* 27(8):1160–1167
20. Hoeflich KP et al (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. *Clin Cancer Res* 15(14):4649–4664
21. Reich M et al (2006) GenePattern 2.0. *Nat Genet* 38:500–501
22. Mermel CH et al (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol* 12(4):R41
23. Marcotte R et al (2012) Essential gene profiles in breast, pancreatic, and ovarian cancer cells. *Cancer Discov* 2(2):172–189
24. Perou CM et al (2000) Molecular portraits of human breast tumours. *Nature* 406(6797):747–752
25. Chapman NM et al (2015) Proline-rich tyrosine kinase 2 controls PI3-kinase activation downstream of the T cell antigen receptor in human T cells. *J Leukoc Biol* 97(2):285–296
26. Izumchenko E et al (2009) NEDD9 promotes oncogenic signaling in mammary tumor development. *Cancer Res* 69(18):7198–7206
27. Jafarnejad SM et al (2013) Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. *Cell Mol Life Sci* 70(15):2677–2696
28. Vervoort SJ, van Boxtel R, Coffey PJ (2013) The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? *Oncogene* 32(29):3397–3409
29. Miller TW et al (2009) Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. *Cancer Res* 69(10):4192–4201
30. Nagata Y et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 6(2):117–127
31. Perez-Tenorio G, Stal O (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. *Br J Cancer* 86(4):540–545
32. Stemke-Hale K et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 68(15):6084–6091
33. Bachman KE et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. *Cancer Biol Ther* 3(8):772–775
34. Campbell IG et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. *Cancer Res* 64(21):7678–7681
35. Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 366(6):520–529
36. Piccart M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 dagger. *Ann Oncol* 25(12):2357–2362
37. Zardavas D, Fumagalli D, Loi S (2012) Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers? *Curr Opin Oncol* 24(6):623–634
38. Zhang J et al (2012) SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. *Cancer Res* 72(17):4597–4608
39. Rhodes DR et al (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. *Proc Natl Acad Sci USA* 101(25):9309–9314
40. Liu P et al (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. *Cancer Res* 66(8):4011–4019
41. Tavazoie SF et al (2008) Endogenous human microRNAs that suppress breast cancer metastasis. *Nature* 451(7175):147–152
42. Tiwari N et al (2013) Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. *Cancer Cell* 23(6):768–783
43. Ikushima H et al (2011) Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. *J Biol Chem* 286(48):41434–41441
44. Ramezani-Rad P et al (2013) SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. *Blood* 121(1):148–155
45. Bilir B et al (2016) SOX4 is essential for prostate tumorigenesis initiated by PTEN ablation. *Cancer Res* 76(5):1112–1121
46. Liao YL et al (2008) Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. *Oncogene* 27(42):5578–5589
47. Yeh ES et al (2013) Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten. *Proc Natl Acad Sci USA* 110(15):6103–6108
48. Scharer CD et al (2009) Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. *Cancer Res* 69(2):709–717